Adipose | Normal | 37 | 366 | 259–591 | | |
Lipomas and lipomatosis | 7 | 189 | 116–969 | 0.377 | |
Adrenal | Normal | 10 | 499 | 249–616 | | |
1° malignancy, no metastasis* | 10 | 337 | 242–576 | 0.257 | |
Benign tumours | 4 | 374 | 59–755 | 0.671 | |
Blood vessels | Normal | 11 | 113 | 74–281 | | |
Bone | Normal | 2 | 157 | 125–189 | | |
1° malignancy, no metastasis* | 25 | 191 | 121–632 | 0.517 | 0.767 |
Metastatic disease | 7 | 225 | 118–820 | 0.380 | |
Benign tumours | 5 | 85 | 65–122 | 0.190 | |
Bone marrow | Normal | 5 | 185 | 126–289 | | |
Breast | Normal | 33 | 166 | 129–211 | | |
1° malignancy, no metastasis* | 276 | 240 | 160–362 | 0.0001 | 0.197 |
Metastatic disease | 21 | 187 | 96–412 | 0.495 | |
Fibroadenomas | 9 | 177 | 159–243 | 0.450 | |
Cystosarcoma phyllodes | 3 | 341 | | 0.041† | |
Cell lines | Normal | 99 | 81 | 44–156 | | |
Untreated malignant | 110 | 108 | 62–263 | 0.001 | |
Cervix | Normal | 66 | 217 | 163–280 | | |
1° malignancy, no metastasis* | 20 | 294 | 182–451 | 0.011 | 0.699 |
Metastatic disease | 4 | 322 | 219–437 | 0.105 | |
Central nervous system | Normal | 160 | 111 | 78–157 | | |
1° malignancy, no metastasis* | 21 | 113 | 58–607 | 0.651 | 0.386 |
Meningiomas | 10 | 48 | 27–135 | 0.009 | |
Colorectal | Normal | 222 | 150 | 112–203 | | |
1° malignancy, no metastasis* | 158 | 331 | 238–466 | <0.0001 | 0.001 |
Metastatic disease | 34 | 479 | 291–725 | <0.0001 | |
Benign tumours | 19 | 255 | 202–358 | 0.0003 | |
Endometrium | Normal | 7 | 452 | 238–563 | | |
1° malignancy, no metastasis* | 96 | 330 | 212–507 | 0.455 | |
Metastatic disease | 12 | 396 | 246–476 | 0.735 | |
Gallbladder | Normal | 8 | 607 | 506–666 | | |
Head and neck | Normal | 14 | 140 | 110–179 | | |
1° malignancy, no metastasis* | 30 | 228 | 145–308 | 0.002 | 0.326 |
Metastatic disease | 22 | 316 | 153–421 | 0.003 | |
Benign tumours | 21 | 244 | 140–384 | 0.005 | |
Heart | Normal | 15 | 345 | 305–456 | | |
Kidney | Normal | 76 | 462 | 382–532 | | |
1° malignancy, no metastasis* | 85 | 1461 | 383–2435 | <0.0001 | 0.936 |
Metastatic disease | 6 | 1407 | 166–2985 | 0.170 | |
Oncocytomas | 8 | 778 | 492–1017 | 0.01 | |
Other benign tumours | 4 | 162 | 111–230 | <0.0001 | |
Liver | Normal | 43 | 533 | 390–583 | | |
1° malignancy, no metastasis* | 18 | 435 | 315–617 | 0.282 | 0.130 |
Metastatic disease | 7 | 341 | 126–478 | 0.020† | |
Lung | Normal | 100 | 438 | 354–567 | | |
1° malignancy, no metastasis* | 123 | 390 | 223–591 | 0.101 | 0.820 |
Metastatic disease | 5 | 348 | 107–894 | 0.588 | |
Lymphoid | Normal | 44 | 230 | 162–309 | | |
1° malignancy, no metastasis* | 78 | 55 | 29–100 | <0.0001 | 0.024† |
Metastatic disease | 3 | 225 | 89–432 | 0.828 | |
Muscle (skeletal) | Normal | 31 | 389 | 280–587 | | |
Myometrium | Normal | 140 | 718 | 531–888 | | |
1° malignancy, no metastasis* | 2 | 1201 | 779–1623 | 0.156 | 0.079 |
Metastatic disease | 7 | 246 | 100–561 | 0.009 | |
Leiomyoma | 50 | 485 | 289–712 | <0.0001 | |
Neuroendocrine | 1° malignancy, no metastasis* | 14 | 236 | 158–374 | | 0.166 |
Metastatic disease | 3 | 373 | 332–393 | | |
Oesophagus | Normal | 18 | 271 | 181–493 | | |
1° malignancy, no metastasis* | 17 | 544 | 388–843 | 0.006 | 0.923 |
Ovary | Normal | 117 | 95 | 62–166 | | |
1° malignant disease | 94 | 329 | 202–523 | <0.0001 | 0.764 |
Metastatic disease | 61 | 356 | 185–532 | <0.0001 | |
Benign tumours | 48 | 136 | 69–201 | 0.089 | |
Pancreas | Normal | 34 | 446 | 319–512 | | |
1° malignancy, no metastasis* | 52 | 428 | 320–517 | 0.818 | 0.768 |
Metastatic disease | 20 | 430 | 363–510 | 0.962 | |
Adenomas | 5 | 428 | 264–2812 | 0.669 | |
Placenta | Normal | 4 | 62 | 42–69 | | |
Prostate | Normal | 34 | 795 | 469–1083 | | |
1° malignancy, no metastasis* | 65 | 520 | 267–803 | 0.004 | 0.665 |
Metastatic disease | 3 | 668 | 300–922 | 0.404 | |
Benign prostatic hypertrophy | 31 | 464 | 267–618 | 0.003 | |
Prostatic intraepithelial neoplasia | 4 | 1374 | 749–1574 | 0.092 | |
Skin | Normal | 55 | 120 | 87–140 | | |
1° malignant disease | 38 | 191 | 108–331 | <0.0001 | 0.645 |
Metastatic disease | 22 | 166 | 87–355 | 0.025† | |
Small intestine | Normal | 129 | 230 | 181–301 | | |
1° malignancy, no metastasis* | 6 | 196 | 105–281 | 0.245 | 0.134 |
Inflammatory bowel disease | 4 | 97 | 77–251 | 0.041† | |
Adenomatous polyps | 6 | 202 | 145–278 | 0.417 | |
Soft tissue | 1° malignancy, no metastasis* | 58 | 300 | 156–596 | | 0.275 |
Metastatic disease | 15 | 464 | 216–764 | | |
Benign tumours | 39 | 149 | 91–242 | | |
Stomach | Normal | 23 | 374 | 284–465 | | |
1° malignancy, no metastasis* | 57 | 288 | 215–366 | 0.009 | 0.141 |
Metastatic disease | 13 | 193 | 112–373 | 0.012 | |
Testis | Normal | 15 | 177 | 94–199 | | |
1° malignancy, no metastasis* | 18 | 52 | 22–161 | 0.010 | 0.465 |
Thymus | Normal | 65 | 25 | 19–34 | | |
1° malignancy, no metastasis* | 3 | 28 | 21–341 | 0.395 | |
Thyroid | Normal | 11 | 1212 | 567–1388 | | |
1° malignant disease | 26 | 534 | 293–973 | 0.003 | 0.242 |
Metastatic disease | 9 | 464 | 226–601 | 0.001 | |
Nodular hyperplasia | 15 | 668 | 592–914 | 0.002 | |
Benign tumours | 8 | 1448 | 867–1388 | 0.206 | |
Urinary | Normal | 7 | 170 | 115–421 | | |
1° malignancy, no metastasis* | 24 | 531 | 281–868 | 0.005 | 0.817 |
Metastatic disease | 3 | 579 | 131–2033 | 0.210 | |
White blood cells | Normal | 79 | 21 | 9–45 | | |
1° malignancy, no metastasis* | 6 | 164 | 117–240 | 0.001 | |